Inhibiting mutant IDH-1
AssigneeFORMA Therapeutics, Inc.
InventorsPatrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Life of this patent
Estimating the term…
Abstract
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Claims10
A method of treating a patient diagnosed with acute myeloid leukemia (AML) having an IDH1 mutation, the method comprising administering to the patient in need thereof 150 mg of the compound of Formula (1) twice per day (BID):
A method of treating a patient diagnosed with relapsed or refractory acute myeloid leukemia (AML) having an IDH1 mutation, the method comprising orally administering to the patient in need thereof a pharmaceutical composition comprising 150 mg of the compound of Formula (1) twice per day (BID):
- in an oral unit dosage form, on consecutive days throughout a course of treatment of at least 15 consecutive days.
Dependencies are inferred from the claim text.